Volume 3 | Issue 1 | DOI: https://doi.org/10.33696/cardiology.3.029
Should we Target Myostatin, PCSK9 or Their Combination in Ischemia or Reperfusion Injury?
- 1Department of Surgical and Integrated Diagnostic Sciences, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, Italy
- 2Vascular and Endovascular Surgery Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy
- 3Research Center for Biologically Inspired Engineering in Vascular Medicine and Longevity, University of Genoa, Via Montallegro 1, 16145 Genoa, Italy
Chiara Barisione, firstname.lastname@example.org
Received Date: April 08, 2022
Accepted Date: May 17, 2022
Barisione C, Palombo D. Should we Target Myostatin, PCSK9 or their Combination in Ischemia/Reperfusion Injury? J Clin Cardiol. 2022;3(1):21-24.
Copyright: © 2022 Barisione C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Coronary artery disease and acute myocardial infarction are a leading cause of morbidity and mortality. Contemporary therapy is percutaneous coronary intervention (PCI), performed by balloon angioplasty and stent placement.
Ischemia/reperfusion (I/R) injury is the consequence of a transient interruption of the blood supply for pathologic, traumatic or surgical reasons, followed by flow restoration with rapid hemodynamic changes in the downstream tissues and organs.
Cytokines (IL-1 β, IL-6, IL-18, TNF-α) in Blood and Cerebrospinal Fluid in Neonatal Hypoxia/Ischemia)
Perinatal brain injury is an important clinical and socioeconomic entity. It is a syndrome of impaired brain function in the early days of life, and it is a consequence of inadequate brain oxygenation before, during or shortly after birth, with high mortality rates and early and late morbidity rates.
Beta 3-Adrenergic Receptor (β3-AR) Activation at the End of Sustained Ischemia and/or Early Reperfusion may Prove to be a Valuable Cardioprotective Strategy
The contribution of β3-AR activation towards ischemiareperfusion (IR) damage largely depends on the disease stage, severity, experimental model as well as drug specificities which should be considered when investigating β3-AR pharmacology for potential therapeutic applications. These conceptions largely contribute to the discrepancies of the subsequent role of β3-AR activation in the cardiovascular disease process.